Clinical Trial Update: Budesonide for Liver Transplant Immune Suppression [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating budesonide for liver transplant immune suppression has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cellular Graft Rejection
• Liver Transplant Rejection
• New-onset Diabetes After Transplantation

Drugs mentioned

• Budesonide (BUDESONIDE)

Snippet

Sponsor: University of Cincinnati | Conditions: Acute Cellular Graft Rejection, New Onset Diabetes After Transplant | Phase 2 | Status: COMPLETED | Results posted: 2021-07-20